Bicocca Open Archive

Logo unimib boa
CAIROLI, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 16.268
NA - Nord America 8.500
EU - Europa 7.358
SA - Sud America 2.123
AF - Africa 317
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 2
Totale 34.596
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.166
SG - Singapore 5.829
CN - Cina 3.259
HK - Hong Kong 2.880
IT - Italia 2.685
RU - Federazione Russa 1.888
BR - Brasile 1.673
VN - Vietnam 1.574
IE - Irlanda 899
KR - Corea 761
BD - Bangladesh 477
FR - Francia 375
DE - Germania 346
IN - India 328
ID - Indonesia 249
GB - Regno Unito 239
SE - Svezia 200
FI - Finlandia 172
AR - Argentina 165
CA - Canada 155
IQ - Iraq 148
TR - Turchia 119
NL - Olanda 112
MX - Messico 104
PK - Pakistan 101
ZA - Sudafrica 99
AT - Austria 86
EC - Ecuador 83
UA - Ucraina 79
PH - Filippine 73
ES - Italia 71
SA - Arabia Saudita 71
JP - Giappone 60
UZ - Uzbekistan 51
CO - Colombia 50
VE - Venezuela 48
MA - Marocco 45
TN - Tunisia 36
MY - Malesia 32
CL - Cile 31
EG - Egitto 31
PL - Polonia 31
CH - Svizzera 30
JO - Giordania 30
KE - Kenya 30
AU - Australia 25
PE - Perù 24
PY - Paraguay 24
NP - Nepal 21
AZ - Azerbaigian 20
ET - Etiopia 20
KZ - Kazakistan 19
JM - Giamaica 18
LB - Libano 18
AE - Emirati Arabi Uniti 16
TW - Taiwan 16
DZ - Algeria 15
TH - Thailandia 15
BE - Belgio 14
IR - Iran 14
OM - Oman 14
AL - Albania 13
LT - Lituania 13
IL - Israele 12
CR - Costa Rica 11
CZ - Repubblica Ceca 11
DO - Repubblica Dominicana 11
BO - Bolivia 10
DK - Danimarca 10
GE - Georgia 10
GR - Grecia 10
PS - Palestinian Territory 10
RO - Romania 10
HR - Croazia 9
HU - Ungheria 9
PT - Portogallo 9
TT - Trinidad e Tobago 9
UY - Uruguay 9
AO - Angola 8
BH - Bahrain 7
LY - Libia 7
BG - Bulgaria 6
NO - Norvegia 6
PA - Panama 6
SY - Repubblica araba siriana 6
GT - Guatemala 5
KW - Kuwait 5
RS - Serbia 5
SN - Senegal 5
BY - Bielorussia 4
HN - Honduras 4
KG - Kirghizistan 4
NI - Nicaragua 4
QA - Qatar 4
BA - Bosnia-Erzegovina 3
GY - Guiana 3
NG - Nigeria 3
UG - Uganda 3
AM - Armenia 2
BN - Brunei Darussalam 2
Totale 34.542
Salva come PNG Salva come JPEG
Città #
Singapore 3.219
Hong Kong 2.864
Hefei 1.391
San Jose 1.250
Milan 851
Dublin 848
Ashburn 794
Seoul 745
New York 506
Ho Chi Minh City 485
Santa Clara 463
The Dalles 457
Chicago 425
Hanoi 393
Los Angeles 307
Lauterbourg 281
Rome 243
Dallas 234
Buffalo 212
Beijing 197
Moscow 195
Jakarta 183
São Paulo 167
Council Bluffs 165
Boardman 154
Turin 131
Ann Arbor 126
Helsinki 119
Frankfurt am Main 116
Nuremberg 112
Shanghai 75
Seattle 70
Haiphong 69
Toronto 66
Da Nang 59
Baghdad 56
Rio de Janeiro 51
London 47
Fairfield 46
Lahore 46
Desio 43
Salt Lake City 43
Chandler 42
Orem 41
Tashkent 41
Figino 40
Amsterdam 39
Houston 39
Naples 39
Vienna 37
Washington 37
Johannesburg 36
Munich 36
Tampa 36
Tokyo 36
Montreal 35
Belo Horizonte 33
Biên Hòa 33
Mumbai 33
Phoenix 33
Dhaka 32
Bologna 31
Guangzhou 31
Atlanta 30
Porto Alegre 30
Amman 29
Brooklyn 29
Chennai 29
Curitiba 29
Lappeenranta 29
Brasília 28
Wilmington 27
Ha Long 26
Quito 26
Riyadh 26
Istanbul 25
New Delhi 25
Boston 24
Jeddah 24
Miami 24
Nairobi 24
Jacksonville 23
Warsaw 23
Ankara 22
Can Tho 22
Guayaquil 22
San Francisco 22
Genoa 21
Hải Dương 21
Salvador 21
Caracas 20
Kent 20
Mexico City 20
Princeton 20
Changsha 19
Delhi 19
Hyderabad 19
Madrid 19
Padua 19
Paris 19
Totale 19.939
Salva come PNG Salva come JPEG
Nome #
Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) 471
Assessing eligibility for treatment in acute myeloid leukemia in 2023 382
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 348
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients 268
The role of quantitative polymerase chain reaction in the management of follicular lymphoma patients 268
Lymphoma’s last therapeutic option: Freeze it! 265
Cerebral Infectious Opportunistic Lesions in a Patient with Acute Myeloid Leukaemia: The Challenge of Diagnosis and Clinical Management 259
Advances in the understanding of molecular genetics and therapy ofRichter transformation in chronic lymphocytic leukemia 253
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 241
Communicating the diagnosis of a hematological neoplastic disease to patients’ minor children: a multicenter prospective study 240
RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia 230
Impact of serial echocardiography in the management of primary cardiac lymphoma 228
Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical Trial 210
Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3 200
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi 199
KIT activating mutations: Incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication 195
Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study 194
Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience 190
A phase I/IIa clinical trial of autologous hematopoietic stem cell transplantation in amyotrophic lateral sclerosis 188
Effectiveness and Tolerability of Dual Antiviral Therapy in Immunosuppressed Patients with Protracted SARS-CoV-2 Infection 186
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial 179
Pirtobrutinib is an Effective Salvage Treatment After Ibrutinib in Bing–Neel Syndrome 177
Fasting and Diet: Overview in Chronic Lymphocytic Leukemia 177
Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination.—Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda 174
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapy 173
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 172
Impaired survival of patients with non donor-specific anti-HLA antibodies before HLA-mismatched allogeneic stem cell transplantation 171
Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review 168
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities 166
Exploring the administrative burden faced by hematologists: a comprehensive study in Italy 164
Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial 164
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial 163
Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy? 157
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 157
Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome 156
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice 154
"Efficient Strategies for the Reuse of Surgical and FFP2/ KN95 Face Masks during the COVID-19 Pandemic: Home-Made and Ecological Choices for the Community" 149
DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma 147
Bone Marrow CD34+/lin− Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subjects 147
Transcriptomic Signature of a Patient with Chronic Lymphocytic Leukemia Exhibiting Profound Fluctuations in the Lymphocytosis during Nutrition and Prolonged Fasting Periods 146
Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) 143
Use of Sorafenib in FLT3-Mutant Myeloid Sarcoma: A Case Report 141
Myeloma’s multiple morphologies 140
Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients 140
In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation 139
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 138
Intrahospital COVID-19 infection outbreak management: Keep calm and carry on 137
Hypoplasia of the Spleen: Rare and Puzzling 134
Cordycepin (3′dA) Induces Cell Death of AC133+ Leukemia Cells via Re-Expression of WIF1 and Down-Modulation of MYC 134
A Nine-Gene Expression Signature Distinguished a Patient with Chronic Lymphocytic Leukemia Who Underwent Prolonged Periodic Fasting 133
Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy 131
Prognostic significance of CD33, CD34 and CD117 expression on bone marrow blasts of patients with Myelodysplastic syndromes 130
Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: Results of an Italian multicenter study 129
Prognostic impact of C-KIT mutations in Core Binding Factor-Leukemia 128
IN ADULT ACUTE MYELOID LEUKEMIA (AML) PERIPHERAL BLOOD MEASURABLE RESIDUAL DISEASE (MRD) BY FLOW CYTOMETRY (FC) IS FEASIBLE AND IS PROGNOSTICALLY RELEVANT 128
Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial 127
How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia 127
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma 126
Plasma cell-directed therapy and anti-HLA antibody production: A successful combination? 126
MIS-A: Beware of non-lymphoma 126
Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study 126
Dual antiviral therapy in haematological patients with protracted SARS-CoV-2 infection 126
Saccharomyces cerevisiae fungemia with granulomas in the bone marrow in a patient undergoing BMT 125
A novel start-loss mutation of the SH2B3 gene in a family with myeloproliferative neoplasms 124
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 123
Occurrence of L1M Elements in Chromosomal Rearrangements Associated to Chronic Myeloid Leukemia (CML): Insights from Patient-Specific Breakpoints Characterization 122
c-kit activating mutations and mast cell proliferation in human leukemia [4] 122
Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an "Old-fashioned" Drug be Effective? 122
Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma 121
SOHO State of the Art Updates and Next Questions: What is Fitness in the Era of Targeted Agents? 120
Clinical Impact of Graft Cryopreservation on Allogeneic Stem Cell Transplantation: An Italian, Registry-Based Study on Behalf of the “Gruppo Italiano Per Il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare” (GITMO) 120
Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol 120
VENETOCLAX IN MULTI-RELAPSED MANTLE CELL LYMPHOMA PATIENTS: A REAL-LIFE MULTICENTRIC EXPERIENCE 117
Duvelisib for the treatment of chronic lymphocytic leukemia 116
Use of Plerixafor in Poor Mobilizer Patients with Myeloma and Lymphoma: Clonogenic Capacity and Engraftment Data 116
Bortezomib with HIG-dose dexamethasone as first line therapy in patients with multiple myeloma candidates to high-dose therapy 116
Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 115
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 113
Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia 113
Multidimensional Results and Reflections on CAR-T: The Italian Evidence 111
Clinical management of peripherally inserted central catheters compared to conventional central venous catheters in patients with hematological malignancies: A large multicenter study of the REL GROUP (Rete Ematologica Lombarda - Lombardy Hematologic Network, Italy) 111
A phase I/II study of NMS-03592088, a FLT3, KIT and CSF1R inhibitor, in patients with relapsed or refractory AML or CMML 111
PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation 110
Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects 109
Targeting CD38 to reduce anti-HLA antibody levels: A new and effective option to be integrated into desensitization protocols? 109
VERY LONG-TERM RESULTS OF ALL-TRANS RETINOIC ACID AND ARSENIC TRIOXIDE IN NON-HIGH RISK ACUTE PROMYELOCYTIC LEUKEMIA: LATEST UPDATE OF THE ITALIAN-GERMAN APL0406 RANDOMIZED TRIAL 109
A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis 109
Fungal infections in hematologic neoplasms: Autopsy findings 108
Response of steroid-refractory chronic graft-versus-host disease to extracorporeal photopheresis correlates with the dose of CD3+ lymphocytes harvested during early treatment cycles 107
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers 107
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 107
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913 107
Duvelisib: A new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia 107
Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H 107
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib? 107
Prognostic impact of immunohistochemical p53 expression in bone marrow biopsy in higher risk MDS: A pilot study 106
PROGNOSTIC CORRELATION OF CELL-OF-ORIGIN AND MYC, BCL-2 AND BCL-6 STATUS IN HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS 106
FZD6 triggers Wnt–signalling driven by WNT10BIVS1 expression and highlights new targets in T-cell acute lymphoblastic leukemia 106
A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS 105
Decisional Role of Interim PET in Relapsed/Refractory Classical Hodgkin Lymphoma Treated with Begev Chemotherapy As First Salvage 105
Totale 15.474
Salva come PNG Salva come JPEG
Categoria #
all - tutte 142.663
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 142.663
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20218 0 0 0 0 0 0 0 0 0 0 0 8
2021/2022121 6 3 15 7 11 10 2 14 7 8 12 26
2022/20231.417 27 57 11 13 9 26 0 151 58 921 64 80
2023/20243.794 57 115 139 106 515 840 653 200 657 104 76 332
2024/20259.731 545 1.184 457 439 783 295 687 221 844 1.048 1.035 2.193
2025/202620.211 2.037 2.311 1.568 2.487 1.507 934 2.639 904 1.528 1.438 774 2.084
Totale 35.625